| Detailed information |
|---|
| CancerLivER ID | 2020 |
| Biomarker | AFP, AFP-L3, PIVKA-II, and Ultrasound |
| Biomarker Name/Symbol (given in Publication) | combination of AFP, AFP-L3 and PIVKA II and Ultrasound |
| Biomolecule | Protein + Technique |
| Subject | Human |
| Degree of Validity | Biomarkers for early HCC detection and validated on independent dataset |
| Experimental Condition | Normal vs cancer |
| Cancer type | Hepatocellular carcinoma |
| Regulation | NA |
| Level of significance | NA |
| Source | Serum |
| PMID | 28757516 |
| Type of Biomarker | Diagnostic |
| Pathway | Downregulate NF-κB signaling pathway. |
| Cohort | NA |
| Sensitivity | 85.60% |
| Specificity | 93.30% |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2017 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT02272504, NCT03460080,NCT03337841 |